AngioDynamics (NASDAQ: ANGO) Stock Faces Sell-Off Despite Revenue Growth in Q1 Fiscal 2027

• H.C. Wainwright lowered its price target for AngioDynamics (NASDAQ: ANGO) to $18.00, suggesting a significant upside from its current share price.
• AngioDynamics reported mixed first-quarter fiscal 2027 results, with an improved adjusted loss of $0.04 per share and revenue growth of 6.90% to $80.90 million.
• Despite positive financial indicators like rising Med Tech revenue and improved gross margin, the stock experienced a sharp sell-off, with shares falling over 21.00% on high trading volume.

AngioDynamics (NASDAQ: ANGO), a leading medical device company known for products like Auryon, AlphaVac, and NanoKnife, recently saw its stock analysis updated. H.C. Wainwright analyst Yi Chen lowered the price target for the company's shares to $18.00 from $19.00. At the reported share price of $10.77, this new target suggests a potential upside of approximately 67.10% above the current stock’s valuation.

This adjustment in the price target follows AngioDynamics' mixed first-quarter fiscal 2027 results. As reported, AngioDynamics posted an adjusted loss of $0.04 per share, an improvement from a $0.10 loss in the prior year. Despite the loss, the company demonstrated strong revenue growth, with revenue rising 6.90% to $80.90 million. An adjusted loss metric provides investors with a clearer view of the company’s underlying operating performance by excluding certain non-recurring costs.

Further highlighting positive trends, Med Tech revenue experienced significant growth, increasing by 13.20%, driven by the strong performance of Auryon, AlphaVac, and NanoKnife products. The company's gross margin also saw a notable improvement, rising by 410 basis points, or 4.10 percentage points, to reach 59.40%. This indicates that AngioDynamics is retaining a larger portion of its sales after accounting for direct production costs. Consequently, its operating loss narrowed to $7.30 million, reflecting improved efficiency.

Despite these stronger financial results, the market reacted with a sharp stock sell-off. As reported, AngioDynamics shares fell more than 21.00% on Thursday, accompanied by a substantial trading volume of approximately 1.94 million shares—nearly 3.80 times its 100-day average. In other company news, AngioDynamics announced the appointment of Eric Honroth as its new president and CEO, effective November 2, succeeding Jim Clemmer.